Recipharm Presents its Sixth Internatio?nal Environmen?tal Award winner
Recipharm AB is proud to announce that its sixth International Environmental Award has been awarded to Ludwig Metz, Associate Director Environmental, Health & Safety, at pharmaceutical company Bristol–Myers Squibb.
The purpose of the the Recipharm International Environmental Award is to encourage and inspire best practice and innovation to promote good examples and to encourage environmental dialog within the pharmaceutical industry.
The prize is awarded annually by Recipharm to the best environmental performance or environmental best practice and innovation by the pharmaceutical industry or the academic community. Since Recipharm was founded in 1995, its commitment to environmental best practice has been a pivotal corporate mission.
Lars Backsell, Chairman of Recipharm, commented: “Ludwig Metz’s longstanding work is an excellent example of how sustainability activities and competence within a private business-focused organisation can inspire and be shared and used throughout society. Ludwig Metz has not only inspired his own company, but also universities, pharmacies and organisations to make positive changes to improve their ways of working with respect to sustainability. Through his ability to turn vision into reality, and through his support to industry stakeholders, he is a role model within the pharmaceutical industry.”
Commenting on winning the award, Ludwig Metz remarked; “The award makes me very proud and is a great honor to receive, especially considering its international and unique characteristics. To my knowledge this is the first time that an “innovative practitioner” has been selected. This Award provides recognition for my work and engagement during the past 20 years to promote effective Sustainability supported by my company, Bristol-Myers Squibb. The Recipharm Environmental Award is an encouragement for me and other professionals to continue developing and sharing innovative programmes to successfully integrate Sustainability and motivate others to participate.”
For the past 26 years, Ludwig Metz has been working in the field of Environment, Health, Safety and Sustainability for the pharmaceutical company Bristol-Myers. He is Associate Director and his play field is Europe. He started his International work in 1996 when he moved to the global acting Corporate Environment, Health, Safety and Sustainability department. Metz has established a complete network of partners in Europe, such as experts at universities, associations and rating companies. He has also supported the development of the sustainable goals and activities of various organisations and universities.
Previous laureates:
2012 Dr Damià Barceló, Director of the Catalan Institute for Water research (ICRA) in Spain
2011 Professor Benoit Roig, École des Hautes Études en Santé Publique, France
2010 Wellcome Trust Sanger Institute, Hinxton, Cambrigde, UK
2009 Professor Klaus Kümmerer, Freiburg University, Germany
2008 Apoteket AB, Sweden
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.